Yee

Healthcare stocks have capped off their best quarter yet, driven by major clinical trial wins and easing regulatory pressures, according to UBS global head of biotechnology equity research Michael Yee. Speaking to CNBC, Yee pointed out that the sector’s momentum received a fresh boost on Monday when President Donald Trump announced voluntary drug-pricing agreements with … Read more